ERBB2 and breast carcinoma: Thus, different nanosystem formulations against breast cancer have emerged to reduce this type of resistance: (1) The combined treatment of IgG-HER2 and DOX produces a synergistic anti-tumour effect against breast tumour cells that overexpress HER2 [107].